Quarterly ResultMay 5, 2026, 07:08 AM
Seres Therapeutics Q1 Net Loss $19.9M; Cash Runway to Q3 2026
AI Summary
Seres Therapeutics reported a net loss of $19.9 million for the first quarter of 2026, a significant shift from the net income of $32.7 million in the same period last year. The company's cash and cash equivalents stood at $29.8 million as of March 31, 2026, with an anticipated cash runway extending through the third quarter of 2026. Operationally, Seres is awaiting clinical data from an investigator-sponsored SER-155 study and is advancing its inflammatory and immunology portfolio, including SER-603, while actively seeking partnerships and financing to support its pipeline.
Key Highlights
- Net loss was $19.9 million for Q1 2026, compared to net income of $32.7 million in Q1 2025.
- Cash and cash equivalents totaled $29.8 million as of March 31, 2026.
- Company expects to fund operations through the third quarter of 2026.
- Research and development expenses increased to $13.2 million in Q1 2026 from $11.8 million in Q1 2025.
- General and administrative expenses decreased to $8.1 million in Q1 2026 from $11.9 million in Q1 2025.
- Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis (15 patients) expected in coming weeks.
- SER-155 is Phase 2 ready for prevention of bloodstream infections in allo-HSCT patients, pending funding.
- Advancing preclinical SER-603 for inflammatory bowel disease with IND-enabling activities.